The entire pharmaceutical sector has surged sharply; what happened?

On Monday, all AH Stocks in the pharmaceutical Sector surged, with innovative drugs performing the strongest. The Yinhua CSI Innovative Drugs Industry ETF collectively rose sharply, driven by three main factors: the relaxation of collective procurement, overseas license authorizations, and improvement in Earnings Reports that will reshape the Industry landscape.

wallstreetcnApr 1 08:38 ET

Two Sessions Time | National People's Congress Representative, Lu Qingguo from Chenguang Biotech Group: Improve the quality standards of Chinese Patent Medicine, regulate the centralized procurement model for Traditional Chinese Medicine, and optimize the

① Lu Qingguo, Director of Chenguang Biotech Group and a representative of the National People's Congress, focused on several recommendations at this year's Two Sessions, including optimizing the procurement mechanism for Traditional Chinese Medicine, enhancing the quality standards for Chinese Patent Medicine, and standardizing the Traditional Chinese Medicine granule industry; ② In addition to recommendations related to the Traditional Chinese Medicine industry, Lu Qingguo prepared several suggestions on rural social retirement insurance, rural medical insurance, and increasing support for companies sanctioned by the United States.

cls.cnMar 2 21:09 ET

Jiangsu Lianhuan Pharmaceutical: After nearly 0.3 billion failed placement, plans to borrow 0.2 billion from Banks for Innovative Drugs project "waiting for rice to cook" | Quick read announcement.

① Following the termination of the fundraising plan through the issuance of Convertible Bonds last year, Jiangsu Lianhuan Pharmaceutical has announced the termination of the plan to raise funds by issuing Stocks to specific targets through a simplified procedure. ② In order to develop Innovative Drugs projects, Jiangsu Lianhuan Pharmaceutical intends to apply for a research and development loan from the Jiangsu branch of the National Development Bank, with a credit amount of 0.24 billion yuan.

cls.cnFeb 24 09:38 ET

Huawei will release AI pathology models, and the Medical Industry is迎来 an important opportunity for intelligent upgrades.

① Huawei's data storage public account released information stating that it will launch the Ruijin pathological model based on the Huawei DCS AI solution. ② Jianghai Securities pointed out that under the guidance of the Health China 2030 Global Strategy, the Medical Industry is ushering in an important opportunity for intelligent upgrades.

cls.cnFeb 13 19:04 ET

The positive rate of influenza viruses nationwide continues to rise, and the sales of Against Influenza drugs continue to grow.

① According to the latest data from the China Center for Disease Control and Prevention, the positivity rate of influenza viruses continues to rise, with over 99% being type A influenza. ② As the number of influenza infections increases, the sales of antiviral drugs against influenza have also been growing recently. Currently, the antiviral flu medications available domestically mainly include Oseltamivir, Abidol, Mabalaosavir, Zanamivir, and Peramivir.

cls.cnJan 5 19:05 ET

The State Council meeting deployed to deepen the regulatory reform of Pharmaceutical and medical instruments, and Institutions indicated that there are significant structural opportunities in the Pharmaceutical Industry.

According to media reports, the recent State Council executive meeting deployed measures to deepen the regulation reform of pharmaceuticals and medical instruments, promoting the high-quality development of the pharmaceutical industry. Orient stated that looking back at 2024, the high base from the past has been digested, and the intra-hospital rigid demand is being released normally. Meanwhile, the Industry Chain of Innovative Drugs and the export of instruments continue to yield results, and the overall growth logic is clearly visible.

cls.cnDec 25, 2024 19:09 ET